January 20, 2026 · Form 4 insider transaction
1315 Capital II, L.P. sold 19,000 shares of Interpace Biosciences, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 28 days after the transaction.
The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.; On January 20, 2026, 19,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 9,405,941 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").; The Series C Convertible Preferred Stock had no expiration date.; These securities are held of record by 1315 Capital II, L.P. (the "Investor"). 1315 Capital GP II, L.P. ("1315 Capital GP") is the general partner of the Investor and 1315 Capital Ultimate Holdings, LLC ("1315 Capital Ultimate") is the general partner of 1315 Capital GP. By virtue of such relationship, each of 1315 Capital GP and 1315 Capital Ultimate may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.; Each of 1315 Capital GP and 1315 Capital Ultimate disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.